Clinical Trial Update: A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

This document reports a Phase 1 trial of MKC-1 in patients with refractory hematologic malignancies, including myelodysplastic syndromes and myelofibrosis, whic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• MKC-1

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Hematological Malignancies, Myelodysplasia | Phase 1 | Status: COMPLETED